The Status Quo Of Oligonucleotides Is Not The Future

The oligonucleotide field is booming, but can manufacturing keep up with demand? Innovators are pushing the boundaries of oligonucleotide therapies, targeting larger patient populations and exploring new frontiers like CRISPR. This shift necessitates a revolution in manufacturing, moving away from traditional methods towards more efficient and sustainable solutions.

This article explores the challenges and opportunities in optimizing oligonucleotide manufacturing spaces. Experts from Asahi Kasei Bioprocess and CRB weigh in on the latest trends, including enzymatic synthesis, advanced drying techniques, and the importance of facility flexibility.

Discover how these companies are collaborating to improve quality, purity, and output while minimizing environmental impact. Learn about the critical considerations for designing facilities that can adapt to future advancements and support the growing demand for these groundbreaking therapies.